CAPLIPOINT - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.7
| Stock Code | CAPLIPOINT | Market Cap | 12,479 Cr. | Current Price | 1,641 ₹ | High / Low | 2,397 ₹ |
| Stock P/E | 34.4 | Book Value | 243 ₹ | Dividend Yield | 0.36 % | ROCE | 28.6 % |
| ROE | 22.0 % | Face Value | 2.00 ₹ | DMA 50 | 1,746 ₹ | DMA 200 | 1,895 ₹ |
| Chg in FII Hold | 0.07 % | Chg in DII Hold | -0.05 % | PAT Qtr | 87.3 Cr. | PAT Prev Qtr | 103 Cr. |
| RSI | 37.9 | MACD | -30.4 | Volume | 85,132 | Avg Vol 1Wk | 70,839 |
| Low price | 1,551 ₹ | High price | 2,397 ₹ | PEG Ratio | 1.57 | Debt to equity | 0.00 |
| 52w Index | 10.6 % | Qtr Profit Var | 16.8 % | EPS | 47.7 ₹ | Industry PE | 27.6 |
📈 Chart & Trend: CAPLIPOINT is trading at ₹1,641, below both its 50 DMA (₹1,746) and 200 DMA (₹1,895). This indicates short-term and medium-term weakness, with the stock trending downward.
📊 Momentum Indicators:
- RSI at 37.9 suggests oversold conditions, potential for rebound.
- MACD at -30.4 shows bearish crossover, confirming short-term weakness.
- Bollinger Bands: Price near lower band, indicating possible mean reversion.
- Volume: Current volume (85,132) is slightly above 1-week average (70,839), showing moderate participation.
🔑 Support & Resistance:
- Support zone: ₹1,600–₹1,620
- Resistance zone: ₹1,740–₹1,760 (near 50 DMA)
- Breakout resistance: ₹1,850–₹1,900
- Long-term support: ₹1,550
📌 Entry & Exit Zones:
- Entry: ₹1,600–₹1,630 (near support)
- Exit: ₹1,740–₹1,850 (resistance zone)
- Stop-loss: ₹1,570
📉 Trend Status: Currently reversing from highs and showing bearish consolidation. Needs a breakout above ₹1,746 (50 DMA) to regain strength.
Positive
- ROCE at 28.6% and ROE at 22% reflect strong operational and shareholder returns.
- Debt-to-equity ratio of 0.00 indicates a debt-free balance sheet.
- EPS of ₹47.7 supports earnings visibility.
- FII holdings increased slightly, showing foreign investor confidence.
Limitation
- Stock P/E of 34.4 is higher than industry average (27.6), indicating premium valuation.
- PEG ratio of 1.57 suggests limited growth relative to valuation.
- Quarterly PAT declined (₹87.3 Cr vs ₹103 Cr), showing earnings pressure.
- DII holdings decreased slightly, showing reduced domestic support.
Company Negative News
- No major recent negative news reported, but earnings decline in the latest quarter is a concern.
Company Positive News
- Debt-free status strengthens financial stability.
- Strong ROCE and ROE highlight efficient capital use.
Industry
- Industry PE at 27.6 vs stock PE at 34.4 shows CAPLIPOINT trades at a premium.
- Pharma sector remains resilient with long-term demand drivers, though valuations are stretched.
Conclusion
⚡ CAPLIPOINT is in a bearish consolidation phase, trading below key moving averages. Entry near ₹1,600–₹1,630 offers margin of safety, with exit targets around ₹1,740–₹1,850. Strong fundamentals and debt-free status support long-term prospects, but premium valuation and recent earnings decline pose short-term risks.
Would you like me to prepare a peer benchmarking overlay comparing CAPLIPOINT with other mid-cap pharma stocks (like Divi’s Labs, Laurus Labs, and Alkem) to highlight relative strength and valuation gaps?